Precision BioSciences, Inc. (DTIL) 25th Annual Needham Virtual Healthcare Conference April 14, 2026 9:30 AM EDTCompany ParticipantsJohn Kelly - CFO ...
Liver fibrosis represents a serious worldwide health issue with a prevalence of around 5% in general populations.1 The most ...
Following favorable phase 1 data showing significant reductions in HBV DNA and RNA, the FDA has fast tracked pevifoscorvir sodium for chronic HBV infection.
Measles is back in the United States. More than 1,500 cases have already been reported in the first months of 2026, putting the country on pace ...
Arbutus Biopharma Corporation (NASDAQ:ABUS) shares climbed 6% on Wednesday after the company revealed it had received Fast ...
Despite new rules, vulnerable groups are often unaware of informed consent and provisions for compensation in case of adverse ...
For years, Yale hepatologist Joseph Lim has studied chronic liver disease, with particular attention to liver cirrhosis, ...
Arbutus Biopharma has won U.S. Food and Drug Administration fast-track designation for its proposed imdusiran treatment for chronic hepatitis B, a serious liver infection. The Warminster, Pa., ...
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results